Details of the Drug Pharmacogenomic Perturbation Atlas

Agomelatine Drug Info

Thymanax; Valdoxan; Agomelatine [INN]; AGO 178; AGO178; S 20098; S20098; AGO-178; Agomelatine(INN); S-20098; Valdoxan (TN); Valdoxan, Melitor, Thymanax, Agomelatine; N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide; N-(2-(7-Methoxy-1-naphthalenyl)ethyl)acetamide; N-(2-(7-Methoxynaphth-1-yl)ethyl)acetamide; N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide

Cross-matching ID

PubChem CID

82148

ChEBI ID

CHEMBL10878

CAS Number

CAS 138112-76-2

TTD Drug ID

D0Y8UB

VARIDT Drug ID

DR00473

INTEDE Drug ID

DR0053

General Information of Drug (ID: DMXYA5K)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.39	0.00e+0	34/36 (94.44%)	RPA3;RFC3;POLE2;...
Cell cycle	2.17	0.00e+0	110/124 (88.71%)	ORC1;MAD2L1;SMC1A;...
Fanconi anemia pathway	2.07	0.00e+0	36/54 (66.67%)	FANCI;RPA3;RAD51;...
Pyrimidine metabolism	1.94	8.14e-3	40/56 (71.43%)	RRM2;ENTPD1;DUT;...
Mismatch repair	1.94	6.51e-3	22/23 (95.65%)	RPA3;RFC3;EXO1;...
Nucleotide excision repair	1.93	5.42e-3	40/47 (85.11%)	RPA3;RFC3;POLE2;...
p53 signaling pathway	1.73	4.42e-2	63/73 (86.3%)	RRM2;IGFBP3;CDK1;...
Fructose and mannose metabolism	-1.73	4.14e-2	30/33 (90.91%)	PFKM;FBP1;KHK;...
Ferroptosis	-1.74	3.81e-2	36/41 (87.8%)	SLC3A2;SLC7A11;SAT1;...
Rheumatoid arthritis	-1.78	3.10e-2	78/93 (83.87%)	ANGPT1;ATP6V1C1;ITGB2;...
Galactose metabolism	-1.79	2.53e-2	26/31 (83.87%)	PGM1;B4GALT2;LALBA;...
Pertussis	-1.82	1.97e-2	64/76 (84.21%)	MAPK3;CALML3;IL23A;...
Leishmaniasis	-1.85	1.89e-2	67/77 (87.01%)	MAPK3;FOS;ITGA4;...
Cholesterol metabolism	-1.85	2.36e-2	44/50 (88%)	LPL;SORT1;LDLRAP1;...
Osteoclast differentiation	-1.91	2.36e-2	117/127 (92.13%)	TGFBR1;LILRB4;SPI1;...
Lysosome	-1.96	1.18e-2	115/128 (89.84%)	GAA;CLN3;CD63;...
Legionellosis	-2.01	2.36e-2	51/57 (89.47%)	NAIP;PYCARD;HSF1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H